Literature DB >> 22452449

Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families.

C Malcolm1, R Hain, F Gibson, S Adams, G Anderson, L Forbat.   

Abstract

AIM: The aim was to describe the nature, frequency, severity and management challenges of symptoms in children with two rare life-limiting conditions [Mucopolysaccharide (MPS) and Batten disease].
METHODS: This was an embedded mixed-method study set in the UK between 2009 and 2011. Twenty-six children from 23 families took part. Seventeen children had an MPS condition [MPS III (Sanfilippo) n = 15; MPS I (Hurler) n = 1; MPS IVA (Morquio); n = 1]. Nine children had Batten disease. Prospective data relating to symptoms were collected over 8 weeks using a symptom diary, and qualitative retrospective interviews with families were conducted. Main outcome measures included frequency, severity rating and identification of most challenging symptoms to manage.
RESULTS: The most common and severe symptoms in MPS III were agitation, repetitive behaviours, hyperactivity and disturbed sleep, and in Batten disease were agitation, joint stiffness, secretions, and disturbed sleep. The data highlighted the high prevalence of behavioural symptoms. Distress caused to families by symptoms was not related simply to their occurrence, but to difficulty in management, likelihood of control and extent to which they signalled disease progression and decline.
CONCLUSION: In challenging contrast to the dominant biomedical framing of these rare conditions it was behavioural symptoms, rather than the physical ones, that families documented as most frequent, severe and challenging to manage. The diary developed for this study has potential use in aiding parents and clinicians to document and communicate concerns about symptoms.
© 2012 The Author(s)/Acta Paediatrica © 2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2012        PMID: 22452449     DOI: 10.1111/j.1651-2227.2012.02680.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

2.  An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep.

Authors:  Nicholas Perentos; Amadeu Q Martins; Robin J M Cumming; Nadia L Mitchell; David N Palmer; Stephen J Sawiak; A Jennifer Morton
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

3.  Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).

Authors:  Sheena Grant; Elaine Cross; James Edmond Wraith; Simon Jones; Louise Mahon; Michelle Lomax; Brian Bigger; Dougal Hare
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

4.  Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment.

Authors:  Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay
Journal:  Neurol Ther       Date:  2020-12-02

5.  Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS).

Authors:  S Somanadhan; P J Larkin
Journal:  Orphanet J Rare Dis       Date:  2016-10-10       Impact factor: 4.123

6.  Pain reporting and analgesia management in 270 children with a progressive neurologic, metabolic or chromosomally based condition with impairment of the central nervous system: cross-sectional, baseline results from an observational, longitudinal study.

Authors:  Stefan J Friedrichsdorf; Andrea C Postier; Gail S Andrews; Karen Es Hamre; Rose Steele; Harold Siden
Journal:  J Pain Res       Date:  2017-07-31       Impact factor: 3.133

7.  Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.

Authors:  Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-06-26       Impact factor: 4.123

Review 8.  Pediatric Palliative Care for Children with Progressive Non-Malignant Diseases.

Authors:  Harold Siden
Journal:  Children (Basel)       Date:  2018-02-20

9.  Challenges of palliative care in children with inborn metabolic diseases.

Authors:  Jessica I Hoell; Jens Warfsmann; Felix Distelmaier; Arndt Borkhardt; Gisela Janßen; Michaela Kuhlen
Journal:  Orphanet J Rare Dis       Date:  2018-07-09       Impact factor: 4.123

10.  Paediatric palliative care: recommendations for treatment of symptoms in the Netherlands.

Authors:  Rutger R G Knops; Leontien C M Kremer; A A Eduard Verhagen
Journal:  BMC Palliat Care       Date:  2015-11-05       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.